Abstract 【Objective】 To explore the efficacy of pyrotinib combined with the TP regimen (paclitaxel plus cisplatin) in the treatment of breast cancer patients.【Methods】 A total of 100 breast cancer patients were divided into the control group and the observation group based on different treatment regimens, with 50 cases in each group. The control group received the TP regimen, while the observation group was treated with pyrotinib combined with the TP regimen. The clinical application effects of different treatment regimens were compared between the two groups.【Results】 The disease control rate, post-treatment serum microRNA-22-3P (miR-22-3P) level, immune indicators CD4+, CD4+/CD8+ ratio, progression-free survival, and overall survival in the observation group were all higher than those in the control group (P<0.05). Meanwhile, the post-treatment cysteine-rich protein 61 (CYR61) level and CD8+ level in the observation group were lower than those in the control group (P<0.05).【Conclusion】 Pyrotinib combined with the TP regimen for breast cancer treatment can effectively increase serum miR-22-3P level, reduce CYR61 level, continuously improve immune function, prolong progression-free survival and overall survival, and it has good safety.
SHI Yushuai,YUE Saichao. Clinical Efficacy of Pyrotinib Combined with TP Regimen in the Treatment of Breast Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 799-801.
2025, Vol. 42 
